In January 2013 the biotechnology company Seattle Genetics selected Clay Siegall, Ph. D., as a director external of the Board of Directors. Siegall is also the co-founder, President, Chief Executive Officer and Chairman of Board of Director of the company. His scientific inventiveness has instituted meticulous research and practices in drug development for Seattle Genetics and patients needing treatment. The company developed ADCETRIS (brentuximab vedotin) that has been approved by the U.S. Food and Drug Administration (FDA) under his direction. Dr. Clay Siegall is also the author of 70 publications and possess 15 patents. His educational background consists of a Ph. D. in Genetics and a B.S. in Zoology.
Dr. Siegall founded Seattle Genetics in 1998 and has assembled antibody-based therapies for cancer patients. His successful drive for integrating medical advancements with biotechnology has impressively and generously led to developing antibody-drug conjugates (ADCs). These ADCs are presently used for cancer treatment. This remarkable accomplishment has been incorporated across internal and collaborator programs that use the company’s technology. He has guided investments coordinating capital growth for the company and earned more than $330 million. The appointment as an outside director of the company’s Board of Directors will benefit the development of microRNA (miRNA) therapeutics which are innovated by another biotechnology company called Mirna.
The function of miRNAs is influencing gene phenotype appearance by interacting with emissary RNAs. This enables miRNAs to control and harmonize cellular pathways in multiple processes effectively and efficiently. The responsibility encompasses embryonic development, immunity, inflammation, and cellular growth. Resulting in patient well-being from preventing the growth and incidence of cancer along with the diffusion of it. Poorly structured miRNAs in tumor cells are also interchanged for maximum benefits.
Mirna has been focusing on service advancement and commercialization for using its biotechnology in miRNA therapeutics. Studies in oncology-directed miRNAs amplify dominance over cancer tumors and resulted in clinical conquest of dissimilar animal studies. The company has hopeful anticipation of moving forward with the promotion of Dr. Clay Siegall because of plausible teamwork expansions with Seattle Genetics. The shared passion for cancer treatment between the companies will assist biotechnology to further integrate with the cancer treatment field constructively. The newfound team collaboration supplies cancer treatments with a positive outlook.